Cargando…
Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors
Pancreatic neuroendocrine tumors are rare and the majority of patients present in the advanced stage. Over the past few decades, treatment for patients with metastatic well- or moderately differentiated pancreatic neuroendocrine tumors have not significantly impeded tumor progression nor improved su...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421470/ https://www.ncbi.nlm.nih.gov/pubmed/22904642 http://dx.doi.org/10.2147/CMAR.S25979 |